The new pacemaker (PM) generations featuring extended memory functions (MF) document the occurrence of arrhythmias over periods of several months. Recordings of all atrial episodes and their characteristics contribute to the efficacious treatment of these patients. However, ventricular arrhythmia (VA) characteristics and occurrences are less well-known in this population. The goal of this study was to evaluate the pertinence of MF at the ventricular level and to describe the MF-documented VAs.
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We suggested being interested in the theoretical and practical aspect of the slew-rate measurement, to obtain an evaluation of the relation between this measure and the other measures done during implantation and follow-up such as the stimulation thresholds, the value of the EGM and the impedance. The variation of this parameter will inform us about the quality of the interface lead/myocardium.
Method:
The study recruited 746 patients not selected a priori, implanted for AV block (51%) or sinus dysfunction (47%). 847 leads were retained to form 3 homogeneous and comparable groups for their physical, electric characteristics and their site of implantation for atrial and ventricular chambers. They correspond to the optimal characteristics (Gr1), acceptable (Gr2) and not acceptable (Gr3) of sensing and pacing parameters usually admitted by the literature.
Results:
For auricular chamber, we retained a priori, 56 leads (Gr1), 168 for (Gr2) and 15 for (Gr3); the factorial discriminate analysis (FDA) was realized from the variables of slew-rate, sensing per and post-op and threshold per and post-op gives us a result of 83.7% of individuals good classified. For the ventricular chamber, we retained a priori, 183 leads (Gr1), 168 (Gr2) and 9 (Gr3); the FDA realized from the same variables gives us a result of 80 % of individuals good classified. The comparison of the averages between groups for every variable shows a significant difference between these groups as well as in the atrial and the ventricular chambers. The data of the others leads (atrium n=94 and ventricle n=154) were affected by the FDA calculation.
Conclusion:
The results shown a correlation between slew-rate and electric parameters per and post-op for the 3 groups for atrial and ventricular chambers; a new standard for sensing, pacing and slew-rate values were defined as optimal, acceptable and no-acceptable. Accessory pathway (AP) ablation is the treatment of choice of symptomatic patients (pts) with a Wolff-Parkinson-White (WPW) syndrome or pts with a malignant form at electrophysiological study (EPS). WPW can reappear after ablation. The purpose of the study was to look for the risk factors of AP reappearance and the clinical consequences.
Methods: AP ablation was performed in 327 pts aged from 8 to 77 years (37±16), with a WPW. Ablation failed in 6 pts. In other pts, the anterograde and retrograde conduction disappeared after AP radiofrequency ablation. Reappearance of AP occurred in 48 pts from several hours to several years. Their data were studied.
Results: There were no significant clinical differences between pts with and without reappearance of AF, concerning the age (33±16 years vs 36±16), the gender (male gender 28/48 vs 166/280), the reason of ablation (spontaneous malignant form: 10/48 vs 70/280; spontaneous AV reentrant tachycardia (AVRT): 29/48 vs 176/280, asymptomatic with electrophysiological signs of malignancy: 9/48 vs 38/280), the location of AP (left lateral AP: 21/48 vs 125/ 280, posteroseptal AP: 22/47 vs 119/280, anteroseptal: AP 5/47 vs 27/280). During the follow up, among 9 of 45 pts asymptomatic before ablation but with only inducible rapid AF at EPS, 2 pts became symptomatic and had inducible AVRT at the control. 29 of 202 pts with spontaneous AVRT presented recurrences of AVRT, except one and a 2 nd procedure was required. Among 10 of 79 with syncope and signs of malignancy or spontaneous rapid AF, 2 pts have lost the signs of malignancy at 2 nd EPS; 2 pts who presented only with rapid AF, had an AP with long refractory period but developed incessant AVRT's; 6 pts had still signs of malignancy, requiring a second procedure.
Conclusions:
There was no significant clinical or electrophysiological cause that explains the reappearance of AP after ablation. The reappearance of conduction is generally associated with reappearance of all properties of AP associated with malignancy or AVRT, except in some cases. Pts without AVRT before ablation may become symptomatic and develop this AVRT after AP ablation. Background: Arrhythmic storm (AS) was defined for the purpose of the present study as the occurrence of frequent episodes (more than 3/day) of hemodynamically destabilizing ventricular tachycardia or ventricular fibrillation requiring immediately electrical cardioversion or defibrillation. The aim of this study was to determine the prevalence, causes and long-term prognosis of AS in patients with dilated cardiomyopathy, in whom an ICD was implanted for primary prevention.
Methods: This observational study compromised 135 pts (114 M, 21 F, 69 ±20 years old). The NYHA class was II (20pts), III (105pts), IV (10pts). The LVEF was 30 ±8%. The F.U period was 25±15 months Results: AS occurred in 8 (6%) pts at an average of 18±7 months after ICD implantation. The mean number of arrhythmic episodes constituting AS was 25 ±22 (range 6 to 82) per pt. Hospital admission was required for 6 pts. The presumed causes of AS were: a) deterioration of the clinical status in 5pts, b) electrolyte disturbances (hypokalemia) in 2pts, c) unknown in 1pt. The LVEF of pts with AS was 23± 9%(p<0.05). The pts with AS caused by wors-
